Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy

consequently in many plasma pools. 2 More refined products (eg, albumin) were, however, consistently TTV-negative. 2,3 These findings confirm longstanding experience, derived from numerous viral validation studies, of the Cohn HSA manufacturing process as one with a high capacity for removing viruses. The explanation for the recent unexpected findings 1 thus remains enigmatic. Using the same 2 TTV primer sets and a third independent in-house primer system, we confirmed earlier reports 2,3 from research groups at regulatory bodies who unanimously found HSA to be TTVnegative.